LONDON, May 14 (Reuters) - U.S. President Donald Trump's

executive order on drug pricing threatens Roche's

planned $50 billion investment in the United States, the company

said on Wednesday.

Trump's order, signed Monday, directs drugmakers to lower

prices of brand-name medicines to align with those in other

wealthy nations. Analysts and legal experts say the policy would

be difficult to implement.

"Should the proposed EO (Executive Order) go into effect,

Roche's ability to fund the significant investments previously

announced in the U.S. will be in question," the company said in

a statement.

Roche said it did not expect the executive order to affect

its business in 2025, and said it would continue engaging with

the Trump administration and Congress.

Roche in April announced it would invest $50 billion in the

U.S. over the next five years, creating more than 12,000 jobs.

It is among several drugmakers, including Eli Lilly ( LLY ),

Johnson & Johnson ( JNJ ) and Novartis, to announce

large-scale U.S. investments in response to Trump's push to

onshore pharmaceutical manufacturing.

Since taking office, Trump has repeatedly threatened to levy

tariffs on medicines and his administration is conducting an

investigation into imports of pharmaceuticals in an effort to

impose tariffs on national security grounds.